---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-104395"
form_type: "8-K"
ticker: "KYNB"
cik: "0000921299"
company_name: "KYNTRA BIO, INC."
filed_at: "2024-09-06T23:59:59+00:00"
generated_at: "2026-05-31T06:09:59.895600+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# FibroGen terminates CFO Juan Graham and CMO Deyaa Adib as part of cost reduction plan

## Summary
- CFO Juan Graham and CMO Deyaa Adib given termination notice on Aug 30, 2024.
- Graham's departure date: Dec 15, 2024; Adib's departure date: Nov 1, 2024.
- Terminations are part of a cost reduction plan initiated Aug 2, 2024.
- Company states decisions not due to any disagreement with executives.
- Both will remain through transition periods.

## SEC filing metadata
- accession: 0000950170-24-104395
- form_type: 8-K
- ticker: KYNB
- cik: 0000921299
- company_name: KYNTRA BIO, INC.
- filed_at: 2024-09-06T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/921299/000095017024104395/0000950170-24-104395-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/921299/000095017024104395/fgen-20240830.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-104395
- JSON: https://secwatch.observer/filing/0000950170-24-104395.json
- Plain text: https://secwatch.observer/filing/0000950170-24-104395.txt

## Key facts
- Executive change
  Deyaa Adib departed as Chief Medical Officer at KYNTRA BIO, INC..
  - Action: provided notice of termination
  - Role: Chief Medical Officer
  source text: the Company provided notice of termination to two executive officers on August 30, 2024, each of whom will remain with the Company through a transition period: Juan Graham, Chief Financial Officer and Deyaa Adib, M.D., Chief Medical Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/921299/000095017024104395/0000950170-24-104395-index.htm
- Executive change
  Juan Graham departed as Chief Financial Officer at KYNTRA BIO, INC..
  - Action: provided notice of termination
  - Role: Chief Financial Officer
  source text: the Company provided notice of termination to two executive officers on August 30, 2024, each of whom will remain with the Company through a transition period: Juan Graham, Chief Financial Officer and Deyaa Adib, M.D., Chief Medical Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/921299/000095017024104395/0000950170-24-104395-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.